Enhertu (fam-trastuzumab deruxtecan-nxki) has received FDA approval for HR-positive, HER2-low, HER2-ultralow metastatic breast cancer.

Dr. Debu Tripathy discusses the FDA approval of Enhertu in unresectable or metastatic hormone receptor HR+, HER2-low or -ultralow breast cancer.

in addition to its existing use for assessing HER2-low status. The FDA's expansion of the diagnostic's label comes after Enhertu (trastuzumab deruxtecan), an HER2-targeting antibody-drug conjugate ...

There are no targeted therapies specifically approved for patients with HER2-ultra-low expression, and approval would move Enhertu up the treatment pathway ahead of chemo. The results reported at ...

Patients with stage IA HER2+ breast cancer and smaller tumors had high BCSS rates whether they received adjuvant chemotherapy or not.

The FDA made strides in R/R T-cell lymphoma and breast cancer. An AI tool aids pathologists and other positive updates in gastric cancer and NSCLC.

Jazz is also advancing zanidatamab in combo with chemo or chemo and trastuzumab in a Phase 3 trial (HER-BC-303) as a treatment for HER2+ breast cancer where disease has progressed on Enhertu and ...

By analyzing ERBB2 mRNA expression data, researchers identified a group of HER2-negative patients with poor outcomes and potential markers of treatment resistance.

Background: Variable rates of HER2 protein overexpression and gene amplification have been reported in advanced ovarian cancers (AOC). Trastuzumab, tested only as a single agent, has been shown to ...

There is a commercial access agreement for olaparib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

the first and only FDA approved companion diagnostic for assessing HER2-low status since 2022, is now also approved to aid in the assessment of HER2-ultralow status for metastatic breast We ...